Neonatal bloodstream infection (BSI) is the most important cause of morbidity and mortality in the neonatal intensive care unit (NICU). Although most neonatal BSIs are primary bacteremia, some are associated with a focus of infection. This distinction is not well characterized. All patients with neonatal late-onset sepsis (LOS) between January 2006 and December 2013 were enrolled. LOS was categorized as a BSI with a concurrent focus of infection if LOS occurred before or within 24 h after the diagnosis of a specific infectious entity, and as “primary bacteremia” if no concurrent focus of infection was identified. Data concerning demographics, hospital course, microbiology, and outcomes were compared via univariate and multivariate analyses. Of 948 episodes of neonatal LOS, 781 (82.4%) were primary bacteremia, whereas 167 (17.6%) were associated with a known focus of infection, including meningitis (n = 51, 5.4%), ventilator-associated pneumonia (VAP) (n = 36, 3.8%), catheter-related bloodstream infections (n = 57, 6.0%), and necrotizing enterocolitis (NEC) (n = 21, 2.2%). The majority of NEC-associated BSIs were caused by gram-negative bacilli (85.7%). Group B streptococcus accounted for nearly one-third of all meningitis cases (29.4%). Although sepsis-attributable mortality was comparable between primary bacteremia and neonatal BSIs with a focus of infection, neonatal BSIs with meningitis, VAP, and NEC had significantly higher rates of infectious complications. The independent risk factors of sepsis-attributable mortality were infectious complications (Odds ratio [OR] 6.98; 95% confidence interval [CI] 3.64–13.39, P < 0.001); history of one or more than one previous episode(s) of BSI (OR 2.40 and 7.40; 95% CI 1.21–4.74 and 3.70–14.78, P = 0.012 and <0.001, respectively); and underlying secondary pulmonary hypertension in neonates (OR 4.77; 95% CI 1.91–11.96, P = 0.001). A considerable proportion of neonatal LOS can be associated with known infectious foci in the NICU. The microbiologic etiology of neonatal LOS with a concurrent focus of infection is significantly different from that of primary bacteremia. Neonatal BSIs with concurrent meningitis, VAP, or NEC are significantly more likely to have infectious complications. This association independently leads to sepsis-attributable mortality.

In this paper, our aim was to investigate the incidence, clinical characteristics, risk factors, and outcomes of recurrent candidemia in children. We retrospectively reviewed all children with candidemia from a medical center in Taiwan between 2004 and 2015. Two episodes of candidemia ≥30 days apart with clinical and microbiological resolution in the interim were defined as “late recurrence”, and those that had 8–29 days apart from previous episodes were defined as “early recurrence”. 45 patients (17.2%) had 57 episodes of recurrent candidemia, and 24 had 28 episodes of late recurrent candidemia. The median time between recurrences was 1.8 months (range: <1 month to 13 months). Of those, 29 had relapsed candidemia and 28 were re-infected by different Candida species (n = 24) or by different strains (n = 4). Recurrent candidemia patients were more likely to require echinocandins treatment, had a longer duration of candidemia, and higher rate of treatment failure (p = 0.001, 0.014, and 0.012, respectively). Underlying gastrointestinal diseases (Odds ratio (OR) 3.84; 95% Confidence interval (CI) 1.81–8.12) and neurological sequelae (OR 2.32; 95% CI 1.15–4.69) were independently associated with the development of recurrent candidemia. 17.2% of pediatric patients with candidemia developed recurrent candidemia, and approximately half were re-infected. Underlying gastrointestinal diseases and neurological sequelae were the independent risk factors for recurrent candidemia.

Background: Preterm birth significantly contributes to mortality and morbidities, with recent studies linking these issues to gut microbiota imbalances. Probiotic supplementation shows promise in mitigating adverse outcomes in preterm infants, but optimal timing and guidelines remain unclear. This study assesses the benefits of probiotic supplementation for preterm infants without consistent guidelines. Methods: This retrospective study examined extremely low-birth-weight (ELBW) infants in neonatal intensive care units from 2017 to 2021. Mortality and preterm-related outcomes were compared between infants receiving probiotics and those not. Subgroup analyses based on probiotic initiation timing were conducted: early (≤14 days), late (>14 days), and non-probiotic groups. Results: The study included 330 ELBW infants: 206 received probiotics (60 early, 146 late), while 124 did not. Probiotic supplementation was associated with lower overall mortality (adjusted OR 0.22, 95% CI 0.09–0.48) and decreased mortality from necrotizing enterocolitis (NEC) or late-onset sepsis (LOS) (adjusted OR 0.12, 95% CI 0.03–0.45). Early probiotics reduced overall mortality, NEC/LOS-related mortality, and NEC/LOS-unrelated mortality. Late probiotics decreased overall mortality and NEC/LOS-related mortality. Early probiotic use also expedited full enteral feeding achievement. Conclusions: Probiotic supplementation reduces mortality and improves feeding tolerance in preterm infants. Establishing guidelines for probiotic use in this population is crucial.

Background: Cerebral blood flow (CBF) is essential for maintaining cerebral metabolism in extremely preterm infants; however, no universally accepted reference standard exists for CBF velocity (CBFV). This study aimed to establish physiological reference patterns of middle cerebral artery CBFV under strictly defined physiological stability using multimodal monitoring. Methods: This post-hoc analysis included extremely preterm infants (gestational age ≤ 28⁺⁶ weeks or birthweight 500–1000 g) from a prospective cohort study. Serial Doppler ultrasonography of the middle cerebral artery was performed along with near-infrared spectroscopy and electrical cardiometry. Normal CBFV datasets were defined based on systemic stability, adequate cardiac output (>150 mL/kg/min), normal regional cerebral oxygen saturation (65–85%), and the absence of major comorbidities. Associations between Doppler parameters and postmenstrual age (PMA) and concurrent weight were analyzed using generalized estimating equations. Results: Forty infants contributed 194 normal CBFV datasets. Physiological reference ranges for peak systolic velocity (PSV), end-diastolic velocity (EDV), mean velocity (MV), resistance index (RI), and pulsatility index (PI) were established across PMA and concurrent weight strata. Both PSV and MV were associated with PMA and concurrent weight (p < 0.01), whereas EDV, RI, and PI were not. Mean blood pressure was not significantly associated with CBFV parameters. Conclusions: PSV and MV were maturation-dependent cerebral perfusion markers. Multimodally defined physiological stability provides a robust framework for establishing clinically relevant reference values for middle cerebral artery CBFV in extremely preterm infants.

To investigate the utility of measuring serum C-reactive protein (CRP) or procalcitonin (PCT) level in conjunction with the Rochester criteria to exclude invasive bacterial infection (IBI) and urinary tract infection (UTI) in neonates aged 8-28 days with fever without an identifiable source of infection (FWSI). The medical records of all neonates aged 8-28 days with FWSI presenting to our pediatric emergency department between January 2018 and December 2022 were analyzed retrospectively. Only those who underwent workup based on the Rochester criteria with the serum biomarkers were included. Our findings were validated in a separate cohort in 2023. In total, 191 neonates were included in the study, 54 (28.27 %) of whom had IBI and/or UTI. Serum biomarkers were analyzed, and higher CRP (p < 0.001) and PCT (p = 0.013) levels were found to be associated with IBI and UTI on multivariate logistic regression analysis. To exclude IBI and UTI, combining the Rochester criteria with a PCT < 0.5 ng/mL (Chang Gung criteria) had a higher negative predictive value (NPV) of 100.00 % than the Rochester criteria alone (93.06 %) and a similar positive predictive value (40.60 % and 41.18 %, respectively). Chang Gung criteria was validated in a cohort of 42 neonates aged 8-28 days with FWSI in 2023. Using PCT at a threshold of 0.5 ng/mL alongside the Rochester criteria (Chang Gung criteria) provides a higher NPV for excluding IBI and UTI in neonates aged 8-28 days with FWSI.